Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 223

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*

Scott, R., Loeys, T., Davies, M. J., Engel, S. S., for the Sitagliptin Study 801 Group · 2008 · Diabetes, Obesity and Metabolism

Abstract

Aim: To assess the addition of sitagliptin to ongoing metformin therapy in patients with type 2 diabetes who were inadequately controlled [haemoglobin A 1c (HbA 1c ) 7–11%] on metformin monotherapy. Methods: Patients (n = 273) on metformin (≥1500 mg/day) were randomized to receive the addition of once‐daily placebo, sitagliptin 100 mg or rosiglitazone 8 mg in a 1 : 1 : 1 ratio for 18 weeks. The efficacy analysis was based on the all‐patients‐treated population using an analysis of co‐variance with change in HbA 1c from baseline as the primary endpoint. Results: The mean baseline HbA 1c was 7.7% for the entire cohort. After 18 weeks, both active add‐on therapies led to greater improvements in HbA 1c from baseline: −0.73% for sitagliptin (p < 0.001 vs. placebo) and −0.79% for rosiglitazone compared with −0.22% for placebo. No difference was observed between the sitagliptin and rosiglitazone treatments (0.06% [95% confidence interval (CI): −0.14 to 0.25]). The proportion of patients achieving an HbA 1c < 7% was greater with sitagliptin (55%) and rosiglitazone (63%) compared with placebo (38%). Body weight increased from baseline with rosiglitazone (1.5 kg) compared with body weight reduction with sitagliptin (−0.4 kg) and placebo (−0.8 kg). The difference in body weight between the sitagliptin and rosiglitazone groups was 1.9 kg (95% CI: 1.3–2.5). In a prespecified analysis, the proportion of patients experiencing a greater than 3‐kg increase in body weight was 21% in the rosiglitazone group compared with 2% in both the sitagliptin and placebo groups. Both active treatments were generally well tolerated, with no increased risk of hypoglycaemia or gastrointestinal adverse events compared with placebo. Conclusions: In this 18‐week study, the addition of sitagliptin was effective and well tolerated in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Treatment with sitagliptin produced similar reductions in HbA 1c compared with the addition of rosiglitazone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2007.00839.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 223

Metadata

Authors
Scott, R., Loeys, T., Davies, M. J., Engel, S. S., & for the Sitagliptin Study 801 Group
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2008-09-15
Volume
10
Issue
10
Pages
959-969
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2158727328
Cited by
223
References
9
FWCI
23.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*. https://app.cochat.ai/papers/10.1111/j.1463-1326.2007.00839.x
The paper
Scott, R., Loeys, T., Davies, M. J., Engel, S. S., & for the Sitagliptin Study 801 Group. (2008). Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2007.00839.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.